Covered recipient · General Payments record
STEPHANIE LYNETTE SCOTT
Physician Assistants & Advanced Practice Nursing Providers Nurse Practitioner
General Payments · PY2021–2024
$510.83
- Reported across 19 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $290.02 | 16 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Novo Nordisk AS | $113.36 | 6 |
| ABBVIE INC. | $48.01 | 2 |
| PFIZER INC. | $29.17 | 2 |
| Astellas Pharma US Inc | $19.03 | 1 |
| SHIELD THERAPEUTICS INC | $19.01 | 1 |
| Lilly USA, LLC | $17.96 | 1 |
| GlaxoSmithKline, LLC. | $15.88 | 1 |
| Esperion Therapeutics, Inc. | $14.38 | 1 |
| Amgen Inc. | $13.22 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (16)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| ABBVIE INC. | $27.52 | 04/02/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1108167152 | CMS |
| ABBVIE INC. | $20.49 | 05/02/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1108167154 | CMS |
| Amgen Inc. | $13.22 | 01/24/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1117678923 | CMS |
| Astellas Pharma US Inc | $19.03 | 08/07/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1139518057 | CMS |
| Esperion Therapeutics, Inc. | $14.38 | 03/27/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1129475976 | CMS |
| GlaxoSmithKline, LLC. | $15.88 | 09/18/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1116516005 | CMS |
| Lilly USA, LLC | $17.96 | 03/15/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135954675 | CMS |
| Novo Nordisk Inc | $20.85 | 01/12/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1100358676 | CMS |
| Novo Nordisk Inc | $18.00 | 03/25/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1100639714 | CMS |
| Novo Nordisk Inc | $16.63 | 04/25/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1100451740 | CMS |
| Novo Nordisk Inc | $16.91 | 06/03/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1100437563 | CMS |
| Novo Nordisk Inc | $20.76 | 08/22/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1100292621 | CMS |
| Novo Nordisk Inc | $20.21 | 10/03/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1100494557 | CMS |
| PFIZER INC. | $13.97 | 02/05/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1131575280 | CMS |
| PFIZER INC. | $15.20 | 09/25/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1131928302 | CMS |
| SHIELD THERAPEUTICS INC | $19.01 | 04/11/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1150127335 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2021, 2022, 2023, 2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.